Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple Negative Breast Cancer|PD-L1 Negative
Interventions: DRUG: Sacituzumab Govitecan|DRUG: Pembrolizumab
Sponsor: Dana-Farber Cancer Institute
Collaborators: Gilead Sciences|Merck Sharp & Dohme LLC